• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by InspireMD Inc.

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SC 13G 1 tm2430043d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    INSPIREMD, INC.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    45779A846

    (CUSIP Number)

     

    November 27, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO.   45779A846Page 2 of 5

     

    CUSIP No.  45779A846
    (1) Names of reporting persons NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,411,636
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,411,636
    (9) Aggregate amount beneficially owned by each reporting person 1,411,636
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 5.22%
    (12) Type of reporting person (see instructions) PN

     

     

     

     

    CUSIP NO.   45779A846Page 3 of 5

     

    Item 1(a). Name of Issuer:
       
      INSPIREMD, INC.  (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
     

    6303 Waterford District Drive, Suite 215

    Miami, Florida 33126

       
    Item 2(a). Name of Person Filing
       
     

    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP (“Nantahala”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

       
    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited partnership.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.0001 par value per share (the “Shares”).

     

    Item 2(e).

    CUSIP Number:
     

     

    45779A846

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

     

     

     

     

    CUSIP NO.   45779A846Page 4 of 5

     

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

    Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of November 27, 2024, Nantahala may be deemed to be the beneficial owner of 1,411,636 Shares. The 1,411,636 Shares includes 949,912 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

       
    Item 4(b).

    Percent of Class:

     

    As of November 27, 2024, each of the Reporting Persons may be deemed to be the beneficial owner of 5.22% of the total number of Shares outstanding.

     

    Item 4(c). Number of shares as to which such person has:
       
     

    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 1,411,636
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 1,411,636
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.  
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      This Item 7 is not applicable.

     

     

     

     

    CUSIP NO.   45779A846Page 5 of 5

     

    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the  issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.  

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  December 4,  2024 NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP
       
      By: /s/ Taki Vasilakis
        Taki Vasilakis
        Chief Compliance Officer Nantahala Capital Management, LLC
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $NSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    SEC Filings

    See more
    • InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      6/24/25 4:21:30 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      6/13/25 9:05:20 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      6/3/25 4:10:37 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

      MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the "Company") (NASDAQ:NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company's C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional Course (LINC) in May 2024. The study, which enrolled 316 patients across 24 sites in the United States and Europe, evaluated the safety and efficacy of CGuard Prime for treating carotid artery stenosis. C

      6/24/25 4:05:00 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

      MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh, CGuard is designed to reduce both early and late embolic events by trapping debris against the vessel wall, preventing plaque prolapse and embolization that can cause stroke. "Securing CE Mark certification under the EU MDR is a ma

      6/13/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

      MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the "Effective Date"). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years. Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotic

      6/3/25 4:05:00 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roubin Gary S bought $126,540 worth of shares (50,000 units at $2.53), increasing direct ownership by 13% to 438,902 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      12/4/23 4:15:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Tommasoli Andrea was granted 232,616 shares, increasing direct ownership by 47% to 727,694 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:33 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Director Berman Michael was granted 32,491 shares, increasing direct ownership by 14% to 264,533 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:18 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • CEO and President Slosman Marvin was granted 558,417 units of Restricted Stock Units, increasing direct ownership by 30% to 2,410,536 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:26 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

      MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the "Effective Date"). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years. Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotic

      6/3/25 4:05:00 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

      MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

      11/25/24 4:05:00 PM ET
      $ABT
      $NSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

      TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS). Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial.

      2/12/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Financials

    Live finance-specific insights

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

      MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approvalAnnounced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use du

      3/12/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InspireMD Inc.

      SC 13G - InspireMD, Inc. (0001433607) (Subject)

      12/4/24 4:31:06 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      11/14/24 6:35:20 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      10/28/24 4:02:11 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care